Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
1999-06-30
2002-05-14
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S465000, C514S252110, C514S252130, C514S253050, C514S253060, C514S253120, C514S254020, C514S254050, C514S254090, C514S254100, C514S254110, C514S255040, C544S357000, C544S360000, C544S363000, C544S366000, C544S368000, C544S370000, C544S373000, C544S376000, C544S379000, C544S380000, C544S384000, C544S385000, C544S397000
Reexamination Certificate
active
06387389
ABSTRACT:
TECHNICAL FIELD OF THE INVENTION
The present invention is directed to sustained-release derivatives of hydroxylated analogs of substituted 1-[2[bis(aryl)methoxy]ethyl]-piperazines and -homopiperazines and their use.
BACKGROUND OF THE INVENTION
Drug abuse is a major public health problem. One of the major drugs of abuse in the U.S. is cocaine. Cocaine is a locomotor stimulant, which acts as a local anesthetic and which inhibits the reuptake of norepinephrine, dopamine and serotonin, presumably by binding to a component of the macromolecular transporter complex that translocates biogenic amines from the synaptic space into the cytosol of the nerve terminus (Galloway,
Trends Pharmacol. Sci
. 8: 451-454 (1988)). The inhibition of norepinephrine reuptake results in sympathomimetic effects. The euphoric and addictive effects of cocaine, however, appear to result primarily from inhibition of mesolimbic dopamine reuptake (Ritz et al.,
Science
237: 1219-1223 (1987); Baumann et al.,
J. Pharmacol. Exper. Ther
. 271(3): 1216-1222 (1994)).
Other evidence indicates that mesolimbic dopamine is a crucial neurochemical mediator of rewarding behaviors, e.g., eating and sex (Wise, “Brain dopamine and reward,”
In Theory in Psychopharmacology
, pp. 103-122, Cooper, ed., Academic Press (1981)). In vivo microdialysis studies have demonstrated that the level of extracellular dopamine increases in the nucleus accumbens of animals engaged in rewarding behavior, such as eating (Hernandez et al.,
Life Sci
. 42: 1705-1712 (1988)) or cocaine self-administration (Hurd et al.,
Neurosci. Lett
. 109: 227-233 (1990)). It is believed that the ability of a drug to elevate the level of mesolimbic extracellular dopamine is critical to its abuse (Di Chiara et al.,
PNAS USA
85: 5274-5278 (1988)) and those drugs that inhibit dopamine reuptake, thereby resulting in addictive and euphorogenic effects, are classified as “type 1 blockers” (Rothman,
Life Sci
. 46: PL-17-PL-21 (1990)).
Increased use of cocaine in the 1980's (Adams et al., “Cocaine: A growing public health problem”
In Cocaine: Pharmacology, Effects and Treatment of Abuse
, NIDA Research Monograph 50, Grabowski, ed., U.S. Gov't Printing Office, Washington, D.C. (1984); and Kozel et al.,
Science
34: 970-974 (1986)) resulted in a parallel increase in cocaine use by opioid-dependent and methadone-maintained patients (Kosten et al.,
Am. J. Drug Alcohol Abuse
12: 1-16(1986);
J. Clin. Psychiatry
48-442-444 (1987); Cushman, Hosp. Community Psychiatry 39: 1205-1207 (1988); and Condelli et al.,
J. Subst. Abuse Treat
. 8: 203-212 (1991)). The increase in use of cocaine has been further compounded by the link between intravenous drug abuse and the spread of HIV. Consequently, public awareness of drug abuse has increased, leading to drug abuse treatment becoming a national priority in the U.S. Accordingly, there is a constant and ever growing need for pharmacotherapies, which enable the treatment of larger numbers of drug abusers than would otherwise be possible with nonpharmacological treatment modalities and which can be coupled with more traditional treatment approaches, such as counseling and rehabilitation.
One pharmacotherapeutic approach is to develop a competitive cocaine antagonist, i.e., a drug that will bind to the dopamine transporter but will not inhibit dopamine reuptake (Rothman et al.,
Pharma. Biochem. & Behav
. 40: 387-397 (1991)). Such a cocaine antagonist would be expected to block cocaine from increasing the level of extracellular dopamine. However, a patient could overcome the inhibitory effect of a competitive cocaine antagonist by self-administering more cocaine.
Another pharmacotherapeutic approach is to develop a noncompetitive cocaine antagonist. The noncompetitive cocaine antagonist would be one that binds to the dopamine transporter with high affinity and dissociates slowly. The noncompetitive cocaine antagonist would then provide a sustained increase in the level of extracellular dopamine, thereby providing the drug abuser with some relief from cocaine-craving due to dopamine deficiency, yet inhibiting cocaine from further elevating the level of extracellular dopamine and increasing the probability of increased toxic side effects.
One such noncompetitive cocaine antagonist is the compound 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-[3-phenylpropyl]piperazine, otherwise known as vanoxerine or GBR 12909 (Rothman et al. (1991), supra; and Rothman et al., WO 91/01732). Vanoxerine is a selective inhibitor of dopamine reuptake and is about 700-fold more potent than cocaine in inhibiting dopamine reuptake in vitro (Andersen,
Eur. J. Pharmacol
. 166: 493-504 (1989)). Unlike cocaine, however, vanoxerine-inhibited dopamine reuptake does not result in addictive and euphorogenic effects and, thus, vanoxerine is considered to be a “type-II blocker” (Rothman (1990), supra). In addition, although cocaine and vanoxerine produce equivalent motor-stimulating effects, vanoxerine must occupy the dopamine transporter to a greater extent than cocaine in order to produce equivalent behavioral effects (Rothman et al.,
Pharmacol. Biochem. & Behav
. 43: 1135-1142 (1992)). Similarly, although cocaine and vanoxerine cause dose-related elevations in extracellular dopamine when given alone, cocaine causes a rapid and short-lived increase in dopamine, whereas vanoxerine causes a low and sustained elevation of dopamine (Baumann et al. (1994), supra).
Recently, the ability of vanoxerine to inhibit “cocaine-maintained responding” without inhibiting “food-maintained responding” was demonstrated in rhesus monkeys (Macaca mulatta) (Glowa et al.,
Exper. & Clin. Psychopharmacology
3(3): 219-231 (1995a)). Subsequent studies showed that repeated treatments of rhesus monkeys with lower doses of vanoxerine could sustain these behaviorally-selective effects (Glowa et al.,
Exper. & Clin. Psychopharmacology
3(3): 232-239 (1995b)).
Another cocaine antagonist is 1-[2-(diphenyl-methoxy)-ethyl]-4-(3-phenylpropyl)homopiperazine, otherwise known as LR1111, which is a homolog of 1-[2-diphenyl-methoxy-ethyl]-4-(3-phenylpropyl)piperazine, otherwise known as GBR12935 (Rothman et al.,
Synapse
14: 34-39 (1993)). LR1111, which differs from GBR12935 by the addition of a methylene group to the piperazine ring, has affinity for the dopamine transporter similar to that of GBR12935 but with significantly higher selectivity (Rothman et al. (1993), supra). In addition, LR1111 is over 4,000-fold more selective for the dopamine transporter than the serotonin and norepinephrine transporters (Rothman et al. (1993), supra).
Other structurally related dopamine reuptake inhibitors are also known. See, for example, van der Zee et al.,
Eur. J. Med. Chem.—Chimica Therapeutica
15(4): 363-370 (1980); van der Zee et al.,
Neuropharmacology
24(12): 1171-1174 (1985); Gootjes et al., EP 0 099 148 (published Jan. 25, 1984); Gootjes et al., U.S. Pat. No. 4,476,129 (issued Oct. 9, 1984); and Matecka et al.,
Med. Chem. Res
. 5: 43-53 (1994).
Unfortunately, some of the above compounds are not suitable for use as pharmacotherapeutic agents because they are not limited in their effect. For example, some of the above compounds have been shown to inhibit both “cocaine-maintained responding” and “food-maintained responding” in monkeys (Glowa et al. (1995b), supra).
Other of the above compounds, although they are limited in effect, are not long-lasting in effect. In other words, use of such compounds requires frequent and regular dosing. Such a characteristic is undesirable for a pharmacotherapeutic agent to be used in the treatment of drug abuse, such as, for example, cocaine abuse, where patient noncompliance is a major issue affecting success of treatment.
In view of the above, there remains a need for a dopamine reuptake inhibitor that binds the dopamine transporter with high affinity, selectivity and specificity and that is long-lasting in effect, such that dosing frequency can be reduced, thereby reducing the potential
Glowa John R.
Lewis David
Matecka Dorota
Rice Kenner C.
Rothman Richard B.
Coleman Brenda
Leydig , Voit & Mayer, Ltd.
The United States of America as represented by the Secretary of
LandOfFree
Sustained-release derivatives of hydroxylated analogs of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained-release derivatives of hydroxylated analogs of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained-release derivatives of hydroxylated analogs of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2902402